Assembly Biosciences (NASDAQ: ASMB) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Assembly Biosciences to similar businesses based on the strength of its dividends, profitability, analyst recommendations, earnings, institutional ownership, valuation and risk.
Valuation & Earnings
This table compares Assembly Biosciences and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Assembly Biosciences||$3.04 million||-$50.92 million||-12.89|
|Assembly Biosciences Competitors||$2.57 billion||$977.16 million||0.71|
Assembly Biosciences’ competitors have higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent recommendations for Assembly Biosciences and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Assembly Biosciences Competitors||63||294||946||27||2.70|
Assembly Biosciences presently has a consensus price target of $35.00, suggesting a potential downside of 0.88%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 17.28%. Given Assembly Biosciences’ competitors higher possible upside, analysts plainly believe Assembly Biosciences has less favorable growth aspects than its competitors.
This table compares Assembly Biosciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Assembly Biosciences Competitors||-538.85%||-41.85%||-24.81%|
Volatility & Risk
Assembly Biosciences has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Assembly Biosciences’ competitors have a beta of 0.85, indicating that their average stock price is 15% less volatile than the S&P 500.
Insider & Institutional Ownership
72.3% of Assembly Biosciences shares are held by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 19.6% of Assembly Biosciences shares are held by insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Assembly Biosciences competitors beat Assembly Biosciences on 7 of the 12 factors compared.
About Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.